Salute e Benessere

Clario Achieves ISO 27001 Certification, Demonstrating Commitment to Information…

The ISO 27001 certification is awarded to organizations that meet stringent criteria for establishing, implementing, maintaining, and continually improving information security management practices. The certification is a testament to Clario's unwavering commitment to maintaining the highest standards of information security for its customers and stakeholders. The ISO 27001 certification is awarded to organizations that meet stringent criteria for establishing, implementing, maintaining, and...

PARP Inhibitors Market to reach over USD 10.31 billion by the year 2031 -…

PARP Inhibitors Market Report Scope: PARP Inhibitors Market Report Scope: Get Sample copy of the Global PARP Inhibitors Market Report at: https://www.insightaceanalytic.com/request-sample/1169 PolyaDP-ribose polymerase (PARP) inhibitors consist of extended chains composed of 17 enzymes, which enable the transport of numerous ADP-ribose units to the intended target proteins. When DNA is harmed by various circumstances, including using multiple anti-cancer medications and...

Internet of Medical Things (IoMT) Market to reach over US$ 385.01 Bn by the year…

Internet of Medical Things (IoMT) Market Report Scope: Internet of Medical Things (IoMT) Market Report Scope: Get a Free Sample Report @ https://www.insightaceanalytic.com/request-sample/1559 Latest Drivers Restraint and Opportunities Market Snapshot: Key factors influencing the global Internet of Medical Things (IoMT) Market are: The following are the primary obstacles to the Internet of Medical Things (IoMT) Market's expansion: Future expansion opportunities...

Digital Diabetes Management Market to reach over USD 49.5 Bn by the year 2031 -…

Digital Diabetes Management Market Report Scope: Digital Diabetes Management Market Report Scope: Recent Developments: Get Free Sample Report @https://www.insightaceanalytic.com/request-sample/1487 Latest Drivers Restraint and Opportunities Market Snapshot: Key factors influencing the digital diabetes management market are: The following are the primary obstacles to the digital diabetes management market 's expansion: Future expansion opportunities for the...

Volpara to Highlight Growing AI Suite for Mammography at ECR 2024, Including New…

Volpara and Lunit® commenced negotiating this distribution agreement prior to entering into a Scheme Implementation Agreement on 14 December 2023 (SIA). This distribution agreement is important to Volpara's ongoing business regardless of whether Lunit acquires Volpara as contemplated in the SIA and allows Volpara to sell Lunit's products immediately. Volpara and Lunit ®commenced negotiating this distribution agreement prior to entering into a Scheme Implementation Agreement on14 December…

Invitation to presentation of Sectra's nine-month interim report 2023/2024

To participate, follow the instructions on Sectra's website investor.sectra.com/q3report2324. The broadcast will be made available on the same webpage after the conference. To participate, follow the instructions on Sectra's websiteinvestor.sectra.com/q3report2324. The broadcast will be made available on the same webpage after the conference. Participation will take place via Microsoft Teams. Questions can be posed using the chat function or by sending questions in advance via email to...

Inside information - BBS-Bioactive Bone Substitutes Plc: Drawdown of an advance…

BBS-Bioactive Bone Substitutes Plc, Company announcement, inside information, 21 February 2024 at 10:30 am EET Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position BBS-Bioactive Bone Substitutes Plc's (“BBS”, “the Company”) has signed the drawdown of the advance of EUR 500.000, pursuant to the terms and conditions of the Financing Agreement between BBS and RiverFort Global Opportunities...

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth…

In this work, the authors showed that glioblastomas and other incurable gliomas can integrate themselves into the function of the brain, and that input from healthy brain cells, normally used in functions such as thinking and memory, drives the progression of gliomas. This is possible by formation of synapses between neurons and cancer cells. In this work, the authors showed that glioblastomas and other incurable gliomas can integrate themselves into the function of the brain, and that input...

Immunovia Publishes Full Year Report for 2023

Significant events after the period Significant events after the period CEO's comments I am proud to report on the transformation Immunovia accomplished in 2023. We have made substantial and rapid progress in developing our next-generation test. We have new leadership and a significantly smaller, more agile, and more productive organization. We have leveraged external partnerships to secure expertise and increase productivity and are exploring commercial partnerships to be ready...

Photocure ASA: Results for the fourth quarter of 2023

Photocure reported total group revenues of NOK 142.5 million in the fourth quarter of 2023 (NOK 104.2 million), and EBITDA* of NOK 29.9 million (NOK -16.9 million), driven by a combination of unit volume growth, price increases and a benefit from foreign exchange. Hexvix/Cysview revenues ended at NOK 114.2 million in the quarter (Q4 2022: NOK 94.9 million). EBIT was NOK 22.5 million (NOK -23.1 million) and the cash balance at the end of the period was NOK 259.5 million. Photocure reported…

Bavarian Nordic delivered record financial results in 2023

Preliminary 2023 results exceed the latest guidance and represent the best-ever financial result in the Company's history driven by extraordinary growth in travel health and a surge in smallpox/mpox vaccine sales.2024 revenue of DKK 5,000-5,300 million and EBITDA of DKK 1,100-1,350 million expected.Focused R&D efforts to drive sustainable value creation within infectious diseases; discontinuing immuno-oncology projects.The Company will host three capital markets days during February...

SciBase: Year-end report

The fourth quarter in figures The fourth quarter in figures January - December in figures Important events during the quarter Important events after the end of the period This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET onFebruary 21, 2024. This year-end report has not been subject...

Global Machine Tools Market worth $104.7 billion by 2030 - Exclusive Report by…

Browse in-depth TOC on "Global Machine Tools Market". Browse in-depth TOC on "Global Machine Tools Market". 204 - Tables 63 - Figures 262 - Pages Global Machine Tools Market Scope: "Automotive and transportation segment is expected to grow at the fastest rate during the forecast period." By end user industry, the automotive and transportation segment is expected to account for the largest share of the machine tools market during the forecast period. The...

Air Dehumidifier Market to Reach $5.2 Billion, Globally, by 2032 at 6.4% CAGR…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A134908 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A134908 Prime determinants of growth Growing health concerns drive the demand for air dehumidifiers as consumers recognize the link between high humidity levels and health issues such as allergies and respiratory problems. Dehumidifiers mitigate mold and dust mites, allergens that...

Mallinckrodt Presents Data on Real-World Outcomes with THERAKOS™ CELLEX™…

DUBLIN, Feb. 21, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced a poster presentation of findings from a systematic literature review and meta-analysis of the safety, efficacy, and real-world outcomes of extracorporeal photopheresis (ECP) treatment for patients with steroid-refractory chronic graft-versus-host disease (SR-cGvHD).1 An analysis of 47 studies reporting on the THERAKOS™ CELLEX™ Photopheresis System showed that treatment of SR-cGvHD…

Calliditas Year-end report, January - December 2023

"In December we were granted full approval by the FDA for TARPEYO - a crowning achievement after many years of striving to bring an approved disease modifying treatment to patients with primary IgAN." "In December we were granted full approval by the FDA for TARPEYO - a crowning achievement after many years of striving to bring an approved disease modifying treatment to patients with primary IgAN." CEO Renée Aguiar-Lucander OUTLOOK FOR 2024 Calliditas expects continued…

PolTREG appoints Dan Shelly as Chief Business Development Officer

Gdańsk, Poland – 21 February 2024– PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune diseases, announces today it has appointed Prof. Daniel Shelly, PhD, MBA, into the role of Chief Business Development Officer, to help PolTREG build the strategic, commercial, research and pharmaceutical partnerships that will enable the company to successfully commercialise its strong pipeline of cell...

EssilorLuxottica and Michael Kors Announce Extended Licensing Partnership

EssilorLuxottica and Michael Kors Announce Extended Licensing PartnershipCharenton-le-Pont, France, and New York, US (February, 21 2024 – 07:00 am CET)- EssilorLuxottica and Michael Kors announced today the renewal of their licensing agreement for the development, production and worldwide distribution of prescription frames and sunglasses under the Michael Kors brand.The renewal will come into effect on January 1, 2025 and cover a period of five years, with an option for a five-year...

ScreenPoint Medical Showcases Transpara® Breast AI Designed to Improve Cancer…

Transpara continues to deliver proven clinical and workflow benefits in mammography screening in global practice and clinical research. These benefits are the subject of 4 presentations and 3 posters to be presented at ECR 2024: Transpara continues to deliver proven clinical and workflow benefits in mammography screening in global practice and clinical research. These benefits are the subject of 4 presentations and 3 posters to be presented at ECR 2024: In the first-of-its-kind randomized...

Rejuvenate Biomed's clinical trial demonstrates the therapeutic potential of…

Sarcopenia, a condition affecting up to 22% of 65-year-olds and 50% of 80-year-olds, is characterized by the progressive loss of muscle strength and physical performance. This decline not only impacts the quality of life but also elevates the risk of falls, disability, and mortality, particularly among the older population. Sarcopenia, a condition affecting up to 22% of 65-year-olds and 50% of 80-year-olds, is characterized by the progressive loss of muscle strength and physical performance...

Sanofi: Information concerning the total number of voting rights and shares -…

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l'Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of 2,529,599,938 € Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced two presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting, February 23-26 in Washington, D.C. A poster presentation by David Fleischer, M.D. of Children's Hospital Colorado will describe the long-term (five-year)...

Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences

Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024 Leerink Partners Global Biopharma Conference 2024 onMonday, March 11, 2024 Audio webcasts of the presentations will be available via the Investors section of the Jazz Pharmaceuticals website athttps://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the website for 30 days. About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global...

Fortrea Increases Patient Access Capabilities and Cold Chain Expertise with…

Fortrea's non-commercial specialty pharmacy expansion delivers flexible, scalable solutions to customers and life-changing medications direct to patients Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the opening of its expanded non-commercial specialty pharmacy,FortreaRx ™, located in Lake Mary, Florida, which offers advanced patient access solutions across the United States, including ambient and cold-chain distribution...

Altri Comunicati